» Articles » PMID: 1573422

Efficacy of Intranasal Administration of Neostigmine in Myasthenic Patients

Overview
Journal J Neurol
Specialty Neurology
Date 1992 Mar 1
PMID 1573422
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The efficacy of intranasally administered neostigmine was tested in 22 patients with generalized myasthenia gravis (MG). Topical therapy to the highly vascularized oropharynx proved to be quickly effective in 5-15 min both clinically and electrophysiologically. Twenty-eight MG patients were then recruited from different centres and their morning doses of oral pyridostigmine were substituted with intranasal neostigmine over a period of 2 or 3 weeks. Intranasal neostigmine proved to be equally efficacious in this regimen. No side-effect was noted even in 4 patients treated in this way for 1 year. Intranasal administration of anti-acetylcholinesterase may be very beneficial: (1) for patients with irregular absorption of oral doses; (2) early in the morning and every time a fast and temporary effect is needed; (3) in bulbar impairment and emergencies, in which a handy atomizer may be life-saving.

Citing Articles

Reversal of experimental paralysis in a human by intranasal neostigmine aerosol suggests a novel approach to the early treatment of neurotoxic envenomation.

Lewin M, Bickler P, Heier T, Feiner J, Montauk L, Mensh B Clin Case Rep. 2014; 1(1):7-15.

PMID: 25356201 PMC: 4184533. DOI: 10.1002/ccr3.3.


Early Treatment with Intranasal Neostigmine Reduces Mortality in a Mouse Model of Naja naja (Indian Cobra) Envenomation.

Lewin M, Samuel S, Wexler D, Bickler P, Vaiyapuri S, Mensh B J Trop Med. 2014; 2014:131835.

PMID: 24955095 PMC: 4052076. DOI: 10.1155/2014/131835.


Intramuscular neostigmine and glycopyrrolate safely accelerated bowel evacuation in patients with spinal cord injury and defecatory disorders.

Rosman A, Chaparala G, Monga A, Spungen A, Bauman W, Korsten M Dig Dis Sci. 2008; 53(10):2710-3.

PMID: 18338263 DOI: 10.1007/s10620-008-0216-z.

References
1.
Aquilonius S, Eckernas S, Hartvig P, Lindstrom B, OSTERMAN P, Stalberg E . Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis. J Neurol Neurosurg Psychiatry. 1983; 46(10):929-35. PMC: 1027607. DOI: 10.1136/jnnp.46.10.929. View

2.
Gotti C, Mantegazza R, Clementi F . New antigen for antibody detection in myasthenia gravis. Neurology. 1984; 34(3):374-7. DOI: 10.1212/wnl.34.3.374. View

3.
Dooley J, Goulden K, Gatien J, Gibson E, Brown B . Topical therapy for oropharyngeal symptoms of myasthenia gravis. Ann Neurol. 1986; 19(2):192-4. DOI: 10.1002/ana.410190214. View

4.
Sghirlanzoni A, Peluchetti D, Mantegazza R, Fiacchino F, Cornelio F . Myasthenia gravis: prolonged treatment with steroids. Neurology. 1984; 34(2):170-4. DOI: 10.1212/wnl.34.2.170. View

5.
Hardy J, Lee S, Wilson C . Intranasal drug delivery by spray and drops. J Pharm Pharmacol. 1985; 37(5):294-7. DOI: 10.1111/j.2042-7158.1985.tb05069.x. View